INFECTIOUS RISKS AND COMPLICATIONS IN ADULT LEUKEMIC PATIENTS RECEIVING BLINATUMOMAB
Background: Blinatumomab is an anti-CD19 immunotherapy approved for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) with significantly increased survival rate. While blinatumomab showed lower rates of infection, neutropenia and mucosal barrier injury versus chemotherapy, its infection...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
PAGEPress Publications
2018-05-01
|
| coleção: | Mediterranean Journal of Hematology and Infectious Diseases |
| Assuntos: | |
| Acesso em linha: | https://www.mjhid.org/index.php/mjhid/article/view/3332 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|